Cabaletta Bio Inc. (NASDAQ:CABA) is one of the top penny stocks to buy in investors’ stock portfolio. On May 14, Cabaletta Bio Inc. (NASDAQ:CABA) delivered positive clinical and translational data from the first four patients in the lowest dose cohort evaluating preconditioning-free (PC-free) rese-cel, an investigational, autologous CAR T cell therapy for the treatment of autoimmune diseases.
It also presented manufacturing and translational data from the first two autoimmune patients treated with rese-cel treated using Cellares Cell Shuttle platform. It became clear that a higher rese-cel dose would be required in the absence of preconditioning. In addition, 50% of the patients demonstrated compelling, drug-free responses for six months.
Consequently, PC-free rese-cel has the potential to enhance access for patients in CAR T centers. The company has already signed a long-term commercial supply agreement that will ensure rese-cel is produced for thousands of patients at the lowest cost of goods, with minimal capital investment.
Cabaletta is on track to announce initial data from the lowest-dose cohort of lupus patients dosed with preconditioning. The company also plans to advance rese-cel toward BLA submission as it eyes a commercial launch.
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies designed to reset the immune system and provide potentially curative treatments for patients with autoimmune diseases.
READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks.
Hedge Fund Resource Center